Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor  Jesper Säfholm,

Similar presentations


Presentation on theme: "Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor  Jesper Säfholm,"— Presentation transcript:

1 Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor  Jesper Säfholm, PhD, Martijn L. Manson, PharmD, Johan Bood, MD, Ingrid Delin, BSc, Ann-Charlotte Orre, MD, Per Bergman, MD, PhD, Mamdoh Al-Ameri, MD, Sven-Erik Dahlén, MD, PhD, Mikael Adner, PhD  Journal of Allergy and Clinical Immunology  Volume 136, Issue 5, Pages e1 (November 2015) DOI: /j.jaci Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Concentration-response curves of agonists in human small bronchi. A, Cumulative addition of PGE2 at baseline in the presence or absence of the selective EP4 receptor antagonist ONO-AE3-208 (1 μmol/L). B, Cumulative addition of PGE2 in the presence or absence of the selective EP2 receptor antagonist PF (1 μmol/L) or ONO-AE3-208 (1 μmol/L) on segments precontracted with histamine (1 μmol/L). C, Cumulative addition of the long-acting β-adrenergic receptor agonist formoterol or the selective EP4 receptor agonist TCS 2510 on segments precontracted with histamine (1 μmol/L). Data on contractions in Fig 1, A, are related to maximum contraction, whereas data in Fig 1, B and C, are expressed in percentages of maximal relaxation from histamine precontraction (see the Methods section). Relaxations were studied in the presence of the selective TP receptor antagonist SQ-29,548 (1 μmol/L). Data represent means ± SEMs (n = 7-10). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Contractions of human small bronchi in response to prostanoids. Concentration response relations for all examined agonists (A), followed by separate investigation of PGE2 (B), 17-phenyl trinor PGE2 (C), AL-8810 (control response in gray-shaded bars; D), PGD2 (E), and U (F) in the presence (black-shaded parts of bars) or absence (open bars) of the selective TP receptor antagonist SQ-29,548 (1 μmol/L), selective EP1 receptor ONO-8130 (1 μmol/L; light gray shading), or selective EP3 receptor antagonist ONO-AE5-599 (1 μmol/L; dark gray shading). The contraction of each segment in all experiments was calculated as a percentage in relation to maximal contraction. All experiments were performed in the presence of the selective EP4 receptor antagonist ONO-AE3-208 (1 μmol/L). Data represent means ± SEMs (n = 8). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Anti-IgE exposure. A, Concentration response of anti-human IgE mAb in the presence or absence of the selective H1 receptor antagonist mepyramine (1 μmol/L), selective TP receptor antagonist SQ-29,548 (1 μmol/L), or selective 5-lipoxygenase–activating protein inhibitor MK-886 (1 μmol/L). B, Time course after anti-IgE exposure (51.8 μg/mL) pretreated with PGE2 ( μmol/L). C, Pretreatment with PGE2 (0.1 μmol/L) during different time points ( minutes). D, In the presence or absence of selective EP2 receptor antagonist PF (1 μmol/L) or selective EP4 receptor antagonist ONO-AE3-208 (1 μmol/L), followed by PGE2 (10 μmol/L) 15 minutes before anti-IgE exposure. Fig 3, B-D, shows experiments performed in the presence of the selective TP receptor antagonist SQ-29,548 (1 μmol/L), and for the experiments shown in Fig 3, B and C, ONO-AE3-208 (1 μmol/L) was included. Contraction of each segment in all experiments was calculated as a percentage in relation to maximal tissue contraction. Data represent means ± SEMs (n = 5-9). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Measurement of released histamine (30 minutes; A) and CysLTs (60 minutes; B) in the presence or absence of PGE2 (100 nmol/L) or a combination of PGE2 and the selective EP2 receptor antagonist PF (1 μmol/L) in relation to tissue wet weight after anti-IgE (51.8 μg/mL) exposure. Data represent means ± SEMs (n = 5). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Concentration-response curve of LTD4 and histamine in the presence or absence of PGE2 (10 μmol/L). All experiments were performed in the presence of the selective TP receptor antagonist SQ-29,548 (1 μmol/L) and selective EP4 receptor antagonist ONO-AE3-208 (1 μmol/L) to allow for comparison with the anti-IgE experiments in Fig 3. Data represent means ± SEMs (n = 8). Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions


Download ppt "Prostaglandin E2 inhibits mast cell–dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor  Jesper Säfholm,"

Similar presentations


Ads by Google